Innovent And Lilly’s Rituximab Candidate Accepted By China’s NMPA

 
• By Akriti Seth
  
Lymphoma
Innovent and Lilly expect their rituximab biosimilar to offer an affordable alternative to non-Hodgkin's lymphoma patients • Source: Shutterstock

More from Regulation

More from Policy & Regulation